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A b s t r A c t
Transcatheter aortic valve implantation (TAVI) is a great alternative treatment option 
in high surgical risk and inoperable patients with severe symptomatic aortic steno-
sis (AS). TAVI is a rapidly emerging technique with a constantly expanding body of 
evidence. However, the devices, which are commercially available and are currently 
used widely, have several major limitations. In particular, the inability to reposition/
retrieve/resheath valves, in addition to several patient selection and procedural limita-
tions, such as the occurrence of moderate to severe paravalvular regurgitation (PVR), 
the risk of annular rupture, atrioventricular (AV) conduction abnormalities with sub-
sequent pacemaker requirement, vascular complications and associated bleeding, cor-
onary ostial obstruction by the valve, stroke, as well as complex delivery processes, are 
expected to be overcome with the newer generation valves. Consequently, a number of 
new transcatheter valve choices have been developed either for clinical study or are in 
the pipeline, that it is hoped to bring meaningful clinical outcomes compared with the 
currently commercially available technology. Early data on design modifications have 
shown significant reductions in adverse outcomes from TAVI.
I N t r O D U c t I O N
Aortic stenosis (AS) is the most common valvular disease in the industrialized 
world. It is more common among the elderly population with critical AS affecting 3% 
of those greater than 75 years of age.1 Despite the fact that its prevalence is constantly 
increasing, a large percentage (~30%) of these patients decline or are denied surgical 
replacement of the aortic valve due to prohibitive or increased surgical risk, mostly 
related to comorbidities. The symptoms of the disease comprise syncopal episodes, 
angina and heart failure. The prognosis of the disease is poor, while the clinical condi-
tion of the patients is rapidly deteriorating. In particular, 50% of patients with syncope 
episodes die within 5 years if they remain untreated. Similarly, 50% of patients with 
angina die within 2 years and 50% of patients with heart failure die within one year. 
Most of them are elderly patients who either have comorbidities or cannot undergo 
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surgery (inoperable). Therefore, the introduction of tran-
scatheter techniques and their ability to be performed in both 
“high-risk” and inoperable patients expanded the management 
options in these patients.
In 1965, the first catheter-mounted valve was reported to be 
implanted via the femoral artery into the descending aorta of an 
animal model, and in 1986, the first catheter based intervention 
for AS was balloon valvuloplasty as described by Alain Cribier.2 
The first catheter-mounted stented valve implantation in hu-
mans was performed in 2000, when a platinum–iridium stent 
with a bovine jugular valve, was implanted into the pulmonary 
artery of a boy with pulmonary atresia by Bonhoeffer and his 
colleagues.3 However, the first transcatheter implantation of 
aortic valve (TAVI) was performed in 2002 via an anterograde 
transvenous approach using the historic Percutaneous Heart 
Valve™ (Percutaneous Heart Valves, Inc., NJ, USA), and the 
first retrograde transarterial approach was performed in 2003.4
Since that time, TAVI has emerged as a very challenging 
treatment option with more than 60,000 TAVI devices being 
implanted using both the anterograde transapical approach 
and retrograde transfemoral and transaortic approaches, due 
to avoidance of sternotomy and cardiopulmonary bypass. This 
potential resulted in many technological advances associated 
with both the valve sizes and morphological characteristics as 
well as with the sheath sizes.
O V E r V I E W  O F  V A L V E  t y P E s
H I s t O r I c A L  VA LV E s  A N D  c O m m E r c I A L Ly 
AVA I L A b L E  VA LV E s  ( F I r s t  g E N E r A t I O N )
The historical valves, the Percutaneous Heart Valve™ 
(Percutaneous Valve Technologies, NJ, USA), the Paniagua 
Heart Valve™ (Endoluminal Technology Research, Miami, 
FL) and the Cribier-Edwards Transcatheter Heart Valve™ 
(Edwards LifeSciences, Irvine, CA, USA) were balloon-ex-
pandable valves.5
The first commercially available valves were the Edwards 
SAPIEN THV™ (Edwards LifeSciences, Irvine, CA, USA) 
(Figure 1) and the Medtronic CoreValve™ (Medtronic, Min-
neapolis, MN, USA). The latter was the only self-expandable 
valve. In particular, CoreValve™ (Figure 2) consists of a supra-
annular bovine (first-generation model) or porcine (second- 
and third-generation models) pericardium valve mounted 
on a self-expanding nickel-titanium alloy frame. The frame 
works with a ‘cell’ design with three distinct zones of varied 
loop strength and radial force. Additionally, the high radial 
force of the central portion, supra-annular positioning of the 
leaflets further minimizes disruption of leaflet configuration 
and coaptation. The cell structure of the stent also facilitates 
conformation to anatomical variance and functions to mini-
mize coronary ostia obstruction.6 Rapid ventricular pacing, 
routinely needed for expansion of valves mounted on stents, 
is not required for both the 26- and 29-mm sized CoreValve 
models, while pacing at rates of 140 beats per minute is still 
recommended for the 31-mm device type. Furthermore, the 
ability to reposition and retrieve the valve up to 1/3 of valve 
length deployment is also claimed. The available sizes of 
CoreValve prosthetic sizes are the 26-, 29- and 31-mm which 
are delivered via an 18Fr Accutrack™ long sheath through 
the femoral artery.7 The design, however, necessitates a ret-
rograde approach, eliminating the possibility of transapical 
access. However, when femoral access is contraindicated, the 
subclavian8,9 and direct aortic approaches are now approved 
and established routes for delivery of this type of valve.10
The aforementioned commercially available devices, that 
are currently used widely, have several major limitations. To 
be more precise, the inability to reposition/ retrieve/ resheath 
FIgUrE 2. Medtronic CoreValve™ (Medtronic, Minneapolis, 
MN, USA) consists of supra-annular bovine (first-generation) 
or porcine (second- and third-generation models) pericardium 
valve mounted on a self-expanding nickel-titanium alloy frame.
FIgUrE 1. Edwards SAPIEN THV™ valve (Edwards LifeS-
ciences, Irvine, CA, USA).
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these valves may result in device embolization or malposition-
ing. In addition, several patient selection and procedural factors 
constitute major limitations of the procedure. In particular, 
patient-prosthesis mismatch (PPM) may lead to the occurrence 
of moderate to severe or severe paravalvular regurgitation 
(PVR), which has been associated with increased mortality at 
two-year follow-up.11 This may require corrective techniques,12-14 
such as post-balloon valvuloplasty, valve-in-valve deployment, 
“Snare (Lasso) technique, “Remove and Reinsert” technique 
or surgery.
At the First Department of Cardiology of Hippokration 
Hospital in Athens, where the CoreValve Medtronic system 
has been used since August 2008, reposition techniques12-14 
(“Snare” technique, “Remove and Reinsert” technique “valve-
in-valve”, “balloon withdrawal”) were required in 11% of 
cases. In all cases, the final angiographic result did not reveal 
significant PVR, immediately or during the short- and long-
term follow-up of patients.
Furthermore, PPM entails the risk of annular rupture due 
to the high radial forces associated with aggressive oversizing 
of the valve prosthesis, especially where balloon expansion 
or balloon valvuloplasty is required.15 Valve and leaflet tissue 
may also provoke coronary ostial obstruction, embolization 
and consequent myocardial infarction.
Moreover, atrio-ventricular (AV) conduction abnormalities 
may develop due to the intimate co-location of the left bundle 
with the base of the interleaflet triangle separating the non-
coronary and right coronary leaflets of the aortic valve with 
subsequent need for permanent pacemaker implantation.6,16 In 
addition, vascular complications and associated bleeding are 
a not infrequent complication of placing large-bore sheaths in 
femoral arteries, especially in often-elderly patients with calcific 
atherosclerotic disease of the peripheral vasculature.17-19 Finally, 
stroke is a significant risk when compared to similar cohorts 
undergoing cardiac surgery. The risk of stroke likely relates to 
embolization of friable material at the time of intervention.20
The above limitations are expected to be overcome with 
newer generation valves that will be discussed below.
c O m m E r c I A L Ly  AVA I L A b L E  s E L F -
E x PA N D A b L E  D E V I c E s :  s E c O N D - g E N E r A t I O N
Medtronic Evolut™ (Medtronic, Minneapolis, MN, 
USA)
Evolut™ is the second-generation CoreValve™ which re-
tains most of the design features of its precursor, including cell 
geometry and preserved skirt height (Figure 3). Nevertheless, 
a number of important technical alterations have been made. 
To be more precise, overall height has been reduced, due to 
a 10 mm shortening of the outflow tract and tailored shape to 
improve fit and the capacity for valve retrieval.21 Additionally, 
the porcine leaflets were treated with alpha-amino oleic acid to 
inhibit calcification, a process that has been extended across the 
entire CoreValve™ family. A first-in-man case report in 2012 
described the successful implantation of a 23 mm CoreValve 
Evolut™, delivered using an 18Fr AccuTrack™ delivery system. 
CE-Mark approval was obtained later that year.
JenaValve (JenaValve Technology GmbH, Munich, 
Germany)
JenaValve™ is a porcine aortic root valve mounted on a low 
profile self-expandable nickel-titanium alloy frame designed for 
anterograde transapical implantation. The leaflets are identical 
to those used in the stentless Élan™ and the stented Aspire™ 
valves (Vascutek, Inchinnan, Renfrewshire, UK). A unique 
aspect of this valve is that it relies on “clip fixation” of the 
prosthesis to native aortic valve leaflets (Figure 4). This reduces 
the requirement for high radial forces and larger contact area 
for securing the device to the aortic annulus complex structures. 
As a result, a shorter stent design minimizes complications 
related to the extension of the valve into the aorta and the 
left ventricular outflow tract (LVOT), such as AV conduction 
defect and coronary obstruction, respectively. Other features 
include three positioning ‘feelers’ extending into the aortic 
root sinus for self-positioning and providing tactile feedback, 
flexible stent posts to minimize leaflet stress and leaflets that 
function early in deployment negating requirement for rapid 
ventricular pacing. The delivery system of the valve includes a 
flexible 32Fr sheathless delivery catheter that obviates the need 
for excessive crimping and profile-minimizing modifications.10
FIgUrE 3. Medtronic Evolut™ (Medtronic, Minneapolis, MN, 
USA) is the second-generation CoreValve™ which cell geome-
try and preserved skirt height. However, overall height has been 
reduced, due to a 10 mm shortening of the outflow tract, and 
tailored shape to improve fit and the capacity for valve retrieval.
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The Jena Valve™ was first implanted in 200922 and a 
multi-center prospective CE-Mark study resulted in approval 
in 2011.23 A post-market registry (JUPITER) is ongoing. A 
feasibility and safety study of the transfemoral route with view 
to CE-Mark approval was planned in 2013.
Symetis Acurate™ (Symetis SA, Ecublens, Switzerland)
The Symetis Acurate™ uses a porcine aortic root valve 
mounted on a self-expandable nickel-titanium alloy stent. The 
shape of the stent body is an hourglass (Figure 5). This facilitates 
the annular fit and three stabilization arches provide tactile 
feedback during positioning and prevent tilting during deploy-
ment. An upper crown provides axial fixation and contributes 
to self-positioning. A polyethylene terephthalate (PET) skirt 
is found on the proximal part of the stent body, both inside 
and outside to prevent PVR. Additionally, this aspect of the 
valve minimally protrudes into the LVOT to decrease AV 
conduction disturbance. The delivery system of the valve is 
loaded and housed on a 28Fr delivery device for anterograde 
transapical access. Consequently, loading of the valve does not 
require excessive crimping. Additionally, the conical shape of 
the delivery catheter purportedly facilitates self-centering.10
Deployment is performed via a rotational knob, which, 
initially, partially unsheathes the valve and releases the stabi-
lization arches followed by the upper crown. Accidental full 
release is guarded by a safety pin. Physiological orientation is 
facilitated by markers that allow for TAVI and native com-
missural alignment and consequently minimize coronary ostia 
compromise. The valve is repositionable and re-sheathable by 
reverse rotation of the delivery knob prior to release.10
Limitations of the valve positioning, include the require-
ment for preceding aggressive valvuloplasty due to the lower 
radial forces during self-expansion of this valve. Additionally, 
stabilization arches make the Symetis Acurate™ of uncertain 
value for valve-in-valve procedures. In particular, the results 
of a first-in-man trial (n = 40) and pilot study (n = 50) were 
combined for submission for CE-Mark approval which was 
achieved in 2011.24 A post-marketing surveillance registry was 
established (Symetis Aortic Valve Implantation Registry) with 
favorable early results after 150 patients.
Early results for a transfemoral system which has recently 
undergone first-in-human trials (n = 20) were presented at 
the TCT 2012 Miami conference and were consistent with 
the transapical results. The delivery system used has an 18Fr 
outer diameter and the valve is available in three sizes to ac-
commodate annulus sizes of 21–27 mm. A CE-Mark study 
for the transfemoral approach began in late 201210 and final 
approval was given in 2013.
Portico™ (St. Jude Medical, St. Paul, MN, USA)
The Portico™ valve is a self-expanding nickel-titanium 
alloy stent with treated bovine pericardium leaflets, designed 
to be fully resheathable, repositionable and retrievable. The stent 
design is similar to the Medtronic CoreValve™ but with a more 
open cell structure (Figure 6). A porcine pericardium (chosen 
for its thin profile) sealing cuff is attached to the inside of the 
frame to minimize the risk of PVR. However, in contrast to 
the CoreValve™, cardiac conduction abnormalities are less 
frequent, probably due to a lower leaflet profile and a more 
vertical ventricular end of the stent, reducing both protrusion 
into and radial force onto the LVOT.25 Furthermore, the 
prominent overlap of the leaflets allows full coaptation despite 
distorted and non-circular anatomy, of particular importance 
due to the lower leaflet profile resulting in intra-annular posi-
tioning. Finally, leaflets function early in deployment and thus 
remove the need for rapid ventricular pacing.
The Portico™ was first implanted in humans in 2011 in a 
small feasibility study of 12 patients in Canada and 10 patients 
in Ireland. A pivotal study began in December 2011 resulting 
FIgUrE 5. Symetis Acurate™ (Symetis SA, Ecublens, Switzer-
land) uses a porcine aortic root valve mounted on a self-expand-
able nickel-titanium alloy stent. The shape of the stent body is an 
hourglass. An upper crown provides axial fixation and contrib-
utes to self-positioning.
FIgUrE 4. JenaValve (JenaValve Technology GmbH, Munich, 
Germany) is a porcine aortic root valve mounted on a low pro-
file self-expandable nickel-titanium alloy frame designed for an-
terograde transapical implantation.
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in CE-Mark approval in 2012 for transfemoral or transapical 
delivery (18Fr and 24Fr sheaths respectively).26
Sadra Lotus™ (Boston Scientific, Natick, MA, USA)
Sadra Lotus™ consists of a woven nickel-titanium alloy 
stent housing bovine pericardium leaflets for transfemoral 
delivery. The valve is pre-loaded on an 18Fr delivery system 
for the transfemoral approach and has full repositioning and 
resheathing capacity (Figure 7). The first-in-human implanta-
tion of the Lotus valve was in 2007, with impressive ongoing 
results at 5-year follow-up.26 These positive results were sup-
ported by early data from a pilot study in 2012, the REPRISE 
I trial (n = 11).27 Recruitment for the REPRISE II trial is now 
completed with the Lotus valve showing good performance in 
the REPRISE II trial.28
Edwards CENTERA™ (Edwards LifeSciences, Irvine, 
CA, USA)
Edwards CENTERA™ is the first self-expanding valve 
produced by Edwards LifeSciences. It is composed of a nickel-
titanium alloy frame and treated trileaflet bovine pericardium. 
The stent features a unique shape with the ventricular edge 
of the valve flared to 29-mm, tapering into the 26- mm ‘waist’ 
and ‘bellying’ out to 28-mm (for the 26-mm valve) (Figure 
8). This purportedly facilitates self-centering of valve in the 
annulus, improved fit and therefore reduces PVR. Addition-
ally, it minimizes protrusion on either side of the annulus. 
Unlike the CoreValve™, this valve is not functional until fully 
deployed and thus requires rapid ventricular pacing due to 
considerable LVOT obstruction. Although the CENTERA™ 
is repositionable and recapturable until final deployment, it is 
only resheathable if less than 70% deployed.29 The valve is 
delivered transarterially with a single-operator, motorized 
system via a 14Fr sheath (Edwards LifeSciences). A CE-Mark 
clinical approval trial was begun in late 2012.29
FIgUrE 8. Edwards CENTERA™, the first self-expanding 
valve produced by Edwards LifeSciences, is composed of a 
nickel-titanium alloy frame and treated trileaflet bovine peri-
cardium. The stent features a unique shape with the ventricular 
edge of the valve.
FIgUrE 7. Sadra Lotus™ (Boston Scientific, Natick, MA, USA) 
consists of a woven nickel-titanium alloy stent housing bovine 
pericardium leaflets for transfemoral delivery.
FIgUrE 6. Portico™ (St. Jude Medical, St. Paul, MN, USA) is 
a self-expanding nickel-titanium alloy stent with treated bovine 
pericardium leaflets, designed to be fully resheathable, reposi-
tionable and retrievable with a more open cell structure compar-
ing to the Medtronic CoreValve™.
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Direct Flow Medical Aortic Valve™ (DFM Inc., Santa 
Rosa, CA, USA)
Direct Flow Medical Aortic Valve™ is a bovine pericar-
dium valve with an entirely non-metallic framework relying 
on sequential inflation of dual rings (ventricular followed by 
aortic) to anchor the prosthesis to the native valve annulus 
(Figure 9). The valve is fully repositionable by deflation of the 
cuffs prior to final anchoring. The purported advantage of such 
a design is minimization of valve migration, dislodgement and 
PVR. This valve also has the theoretical potential to reduce 
cerebrovascular events as the dual rings ‘trap’ the native leaflets 
and may minimize embolization. Moreover, rapid ventricular 
pacing is not required, due to the fact that the valve leaflets are 
functional upon expansion. The first-generation DFM valve 
was evaluated in a feasibility and safety study in 31 patients.30,31 
The safety and efficacy of the second-generation system are 
currently being assessed in the CE Mark, multi-center DIS-
COVER trial32 and were verified in 2013.
Medtronic Engager™ (Medtronic, Minneapolis, MN, 
USA)
Medtronic Engager™ is the first valve from Medtronic for 
transapical access and anterograde approach. It employs a self-
expanding nickel-titanium alloy frame incorporating scalloped, 
full thickness, bovine pericardium leaflets (Figure 10). The 
Engager™ valve is delivered via a 29Fr transapical delivery 
system and a direct aortic delivery system is under develop-
ment. The Engager™ underwent first-in-man implantation in 
2008.26 The Engager™ CE pivotal trial began as a prospective, 
multi-center study involving 120 patients. The 30-day results 
on the first 60 recruited patients have been impressive most 
notably with regard to marked reduction in PVR, an improve-
ment in keeping with the other second-generation transapical 
valves (Acurate™ and JenaValve™).33 The valve obtained CE 
mark approval in 2013.
FIgUrE 10. Medtronic Engager™ (Medtronic, Minneapolis, 
MN, USA) is the first valve from Medtronic for transapical 
access and anterograde approach. It employs a self-expanding 
nickel-titanium alloy frame incorporating scalloped, full thick-
ness, bovine pericardium leaflets.
FIgUrE 9. Direct Flow Medical Aortic Valve™ (DFM Inc., 
Santa Rosa, CA, USA) is a bovine pericardium valve with an 
entirely non-metallic framework relying on sequential inflation 
of dual rings (ventricular followed by aortic) to anchor the pros-
thesis to the native valve annulus.
N E W  E N t r I E s
The Aortx™ valve (Hansen Medical Inc., Mountain View, 
CA, USA) has a solid nickel-titanium alloy panel frame formed 
into a convex triangular shape that is hinged at three points to 
allow rotational crimping and eliminate stress at hinge points. 
The valve cusps do not come in contact with the frame during 
valve opening, which may confer leaflet durability (Figure 11). 
The valve has an 18Fr delivery system and has the potential 
to be recaptured and repositioned. First in human implantation 
occurred in 2006 (n = 8).10
The HLt™ valve (Heart Leaflet Technologies Inc., Maple 
Grove, MN, USA) has porcine leaflets mounted on a self-
expandable nickel-titanium alloy wire stent (Figure 12). The 
valve sits in an intra-annular position and it is suitable for the 
transfemoral route via an 18Fr delivery catheter and is available 
in 21- and 23-mm sizes. The valve is fully repositionable and 
retrievable. Additionally, the leaflets are sewn to flexible post 
to reduce valve and tissue stress. First-in-human implantation 
was performed in 5 patients in 2011. It was planned for this 
new design to undergo pilot trial at the end of 2012.10,34
Additionally, there are other valve devices that have not 
been fully developed such as Vanguard II™ (ValveXchange 
Inc., Aurora, CO, USA) which is a second-generation tran-
scatheter valve, for which a CE-Mark approval trial began in 
2012.10 Similarly, the trinity Heart Valve™ (Transcatheter 
Technologies GmbH, Regensburg, Germany) (Figure 13) is a 
repositionable and retrievable valve with bovine pericardium 
mounted on a self-expanding nickel-titanium alloy frame. It 
has been implanted transapically in a beating heart (without 
the need for rapid ventricular pacing).10 The UcL tAV™ valve 
(University College London, London, UK) comprises leaflets 
composed of a novel biocompatible polymeric nano-composite 
recently developed and patented by University College Lon-
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FIgUrE 12. The HLT™ valve (Heart Leaflet Technologies Inc., 
Maple Grove, MN, USA) has porcine leaflets mounted on a self-
expandable nickel-titanium alloy wire stent. Additionally, the 
leaflets are sewn to flexible post to reduce valve and tissue stress.
FIgUrE 13. Trinity Heart Valve™ (Transcatheter Technologies 
GmbH, Regensburg, Germany) is repositionable and retriev-
able, and has bovine pericardium mounted on a self-expanding 
nickel-titanium alloy frame.
FIgUrE 11. The AorTx™ valve (Hansen Medical Inc., Moun-
tain View, CA, USA) has a solid nickel-titanium alloy panel 
frame formed into a convex triangular shape that is hinged at 
three points to allow rotational crimping and eliminate stress at 
hinge points.
don, which exhibits superior mechanical and surface proper-
ties and has higher resistance to calcification (Figure 14). 
The UCL TAV™ is also fully retrievable and repositionable.10 
Finally, the tissue-engineered heart valves have relied on a 
nickel-titanium alloy stent housing a biodegradable synthetic 
scaffold onto which autologous bone-marrow mononuclear 
cells are implanted (Figures 15 & 16). The inherent advantage 
of this is that the valve maintains repair/regenerative capacity 
potentially overcoming problems related to reduced durability 
secondary to calcification and mechanical stress. This concept 
has been applied to pulmonary valves and vascular grafts, with 
the latter having received FDA approval for clinical applica-
tion. Proof-of-concept for application to TAVI has recently 
been reported in an ovine model.35
c O N c L U s I O N
To conclude, there has been rapid and profound evolution 
of the valve technology, that it is hoped to bring meaningful 
clinical outcomes compared with the currently commercially 
available technology. Early data on design modifications have 
shown significant reductions in adverse outcomes from TAVI.
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FIgUrEs 15 & 16. The tissue-engineered heart valves have relied on a nickel-titanium alloy stent housing a biodegradable synthetic 
scaffold onto which autologous bone-marrow mononuclear cells are implanted. Proof-of-concept for application to TAVI has re-
cently been reported in an ovine model.
FIgUrE 14. The UCL TAV™ valve (University College London, London, UK) comprises leaflets composed of a novel biocompat-
ible polymeric nano-composite recently developed, which exhibits superior mechanical and surface properties and has higher resist-
ance to calcification.
r E F E r E N c E s
 1. Lindman BR, Pibarot P, Arnold SV, et al. Transcatheter versus 
Surgical Aortic Valve Replacement in Patients with Diabetes and 
Severe Aortic Stenosis at High Risk for Surgery: An Analysis 
of the PARTNER Trial. J Am Coll Cardiol 2013 Nov 14. pii: 
S0735-1097(13)06084-1. doi: 10.1016/j.jacc.2013.10.057. 
[Epub ahead of print].
 2. Cribier A, Savin T, Saoudi N, Rocha P, Berland J, Letac B. 
Percutaneous transluminal valvuloplasty of acquired aortic 
stenosis in elderly patients: an alternative to valve replace-
ment? Lancet 1986;1:63-67.
 3. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutane-
ous replacement of pulmonary valve in a right-ventricle to 
pulmonary-artery prosthetic conduit with valve dysfunction. 
Lancet 2000;356:1403-1405.
 4. Paniagua D, Condado JA, Besso J, et al. First human case 
of retrograde transcatheter implantation of an aortic valve 
prosthesis. Tex Heart Inst J 2005;32:393-398.
 5. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous tran-
NEwER GENERATION VALVES FOR TAVI
9
scatheter implantation of an aortic valve prosthesis for calcific 
aortic stenosis: first human case description. Circulation 2002; 
106:3006-3008.
 6. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, 
Anderson RH. Anatomy of the aortic valvar complex and its 
implications for transcatheter implantation of the aortic valve. 
Circ Cardiovasc Interv 2008;1:74-81.
 7. Vavuranakis M, Kalogeras KI, Vrachatis DA, Kariori MG, 
Moldovan C, Stefanadis C. CoreValve deployment during 
cardiopulmonary resuscitation without angiographic injections 
guidance: an additional capability of Accutrak system? Int J 
Cardiol 2012;158:e26-28.
 8. Vavuranakis M, Vrachatis DA, Filis K, Stefanadis C. Trans-
catheter aortic-valve implantation by the subclavian approach 
complicated with vessel dissection and transient left-arm 
paralysis. Eur J Cardiothorac Surg 2011;39:127-129.
 9. Vavuranakis M, Vrachatis DA, Toutouzas K, Economopoulos 
G, Kalogeras KI, Stefanadis C. Successful percutaneous aortic 
valve implantation via a stenotic left subclavian artery access. 
Heart Vessels 2010;25:359-362.
 10. Fanning JP., Platts DG, Walters DL, Fraser JF. Transcatheter 
aortic valve implantation (TAVI): valve design and evolution. 
Int J Cardiol 2013;168:1822-1831.
 11. Jilaihawi H, Makkar RR. Prognostic impact of aortic regur-
gitation after transcatheter aortic valve implantation. Euro-
Intervention 2012;8 Suppl Q:Q31-3.
 12. Vavuranakis M, Vrachatis D, Stefanadis C. CoreValve aortic 
bioprosthesis: repositioning techniques. JACC Cardiovasc 
Interv 2010;3:565; author reply -6.
 13. Vavouranakis M, Vrachatis DA, Toutouzas KP, Chrysohoou C, 
Stefanadis C. “Bail out” procedures for malpositioning of aortic 
valve prosthesis (CoreValve). Int J Cardiol 2010;145:154-155.
 14. Vavuranakis M, Kariori M, Vrachatis D, et al. “Balloon with-
drawal technique” to correct prosthesis malposition and treat 
paravalvular aortic regurgitation during TAVI. J Invasive 
Cardiol 2013;25:196-197.
 15. Pasic M, Unbehaun A, Dreysse S, et al. Rupture of the device 
landing zone during transcatheter aortic valve implantation: a 
life-threatening but treatable complication. Circ Cardiovasc 
Interv 2012;5:424-432.
 16. Vavuranakis M, Kariori M, Voudris V, et al. Troponin levels 
after TAVI are related to the development of distinct electro-
cardiographic changes. Int J Cardiol 2013;167:606-608.
 17. Vavuranakis M, Kariori M, Voudris V, et al. Predictive fac-
tors of vascular complications after transcatheter aortic valve 
implantation in patients treated with a default percutaneous 
strategy. Cardiovasc Ther 2013;31:e46-54.
 18. Vavuranakis M, Kalogeras KI, Vrachatis DA, et al. A modified 
technique to safely close the arterial puncture site after TAVI. 
J Invasive Cardiol 2013;25:45-47.
 19. Vavuranakis M, Kalogeras K, Vrachatis D, et al. Inferior epi-
gastric artery as a landmark for transfemoral TAVI. Optimizing 
vascular access? Catheter Cardiovasc Interv 2013;81:1061-
1066.
 20. Dabrowski M, Witkowski A. Stroke following transcatheter 
aortic valve implantation. Is neuroprotection justified? Postepy 
Kardiol Interwencyjnej 2013;9:376-382.
 21. Sinning JM, Werner N, Nickenig G, Grube E. Medtronic Cor-
eValve Evolut valve. EuroIntervention 2012;8 Suppl Q:Q94-6.
 22. Kempfert J, Rastan AJ, Mohr FW, Walther T. A new self-
expanding transcatheter aortic valve for transapical implan-
tation - first in man implantation of the JenaValve. Eur J 
Cardiothorac Surg 2011;40:761-763.
 23. Treede H, Mohr FW, Baldus S, Rastan A, Ensminger S, Arnold 
M, et al. Transapical transcatheter aortic valve implanta-
tion using the JenaValve system: acute and 30-day results 
of the multicentre CE-mark study. Eur J Cardiothorac Surg 
2012;41:e131-138.
 24. Kempfert J, Rastan AJ, Beyersdorf F, et al. Trans-apical aortic 
valve implantation using a new self-expandable bioprosthesis: 
initial outcomes. Eur J Cardiothorac Surg 2011;40:1114-1119.
 25. Willson AB, Rodes-Cabau J, Wood DA, et al. Transcatheter aor-
tic valve replacement with the St. Jude Medical Portico valve: 
first-in-human experience. J Am Coll Cardiol 2012;60:581-586.
 26. Manoharan G, Spence MS, Rodes-Cabau J, Webb JG. St 
Jude Medical Portico valve. EuroIntervention 2012;8 Suppl 
Q:Q97-101.
 27. Meredith Am IT, Worthley SG, Whitbourn RJ, et al. Trans-
femoral aortic valve replacement with the repositionable Lotus 
Valve System in high surgical risk patients: the REPRISE I 
study. EuroIntervention 2013 Oct 31. pii: 20131009-02. [Epub 
ahead of print]
 28. Tofield A. The Lotus valve for transcatheter aortic valve 
implantation. Eur Heart J 2013;34:2335.
 29. Ribeiro HB, Urena M, Kuck KH, Webb JG, Rodes-Cabau J. 
Edwards CENTERA valve. EuroIntervention 2012;8 Suppl 
Q:Q79-82.
 30. Treede H, Tubler T, Reichenspurner H, et al. Six-month results 
of a repositionable and retrievable pericardial valve for tran-
scatheter aortic valve replacement: the Direct Flow Medical 
aortic valve. J Thorac Cardiovasc Surg 2010;140:897-903.
 31. Schofer J, Schluter M, Treede H, et al. Retrograde transarte-
rial implantation of a nonmetallic aortic valve prosthesis in 
high-surgical-risk patients with severe aortic stenosis: a first-
in-man feasibility and safety study. Circ Cardiovasc Interv 
2008;1:126-133.
 32. Schofer J, Colombo A, Klugmann S, et al. Prospective Multi-
center Evaluation of the Direct Flow Medical(R) Transcatheter 
Aortic Valve. J Am Coll Cardiol 2014;63:763-768.
 33. Holzhey D, Linke A, Treede H, et al. Intermediate follow-up 
results from the multicenter engager European pivotal trial. 
Ann Thorac Surg 2013;96:2095-2100.
 34. Chiam PTL, Ruiz CE. Percutaneous transcatheter aortic 
valve implantation: Evolution of the technology. Am Heart J 
2009;157:229-242.
 35. Rodes-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic 
valve implantation for the treatment of severe symptomatic 
aortic stenosis in patients at very high or prohibitive surgical 
risk: acute and late outcomes of the multicenter Canadian 
experience. J Am Coll Cardiol 2010;55:1080-1090.
